PulseAugur
EN
LIVE 18:45:04

Axsome Therapeutics stock doubles on Alzheimer's drug approval

By PulseAugur Editorial · [1 sources] ·

Axsome Therapeutics has seen its stock price double in the past nine months, reaching a market capitalization of $12.6 billion. This significant growth is largely attributed to the recent FDA approval of its drug Auvelity for treating agitation associated with Alzheimer's disease. The company, which focuses on brain disorder treatments and historically self-funded its development, also has a robust pipeline with potential for annual new drug applications through 2030. AI

RANK_REASON Company stock performance driven by a new drug approval for a significant medical condition. [lever_c_demoted from significant: ic=1 ai=0.0]

Read on Forbes — Innovation →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Axsome Therapeutics stock doubles on Alzheimer's drug approval

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Company stock performance driven by a new drug approval for a significant medical condition. [lever_c_demoted from significant: ic=1 ai=0.0]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, funding
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
99 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. Forbes — Innovation TIER_1 English(EN) · Alex Knapp, Forbes Staff ·

    Why Axsome Stock Has Doubled In Nine Months

    In this week’s edition of InnovationRx, we look at Axsome’s growing pipeline, HistoSonics innovative cancer treatment, state litigation over Medicaid work requirements, and more.

RELATED ENTITIES

RELATED TOPICS